Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463134 | 0.90 | POLB (0.58) | SYKPOLBPPARAATMNTSR1 | |
| SCHEMBL648574 | 0.90 | POLB (0.58) | SYKPOLBPPARAATMNTSR1 | |
| SCHEMBL7512116 | 0.90 | POLB (0.58) | SYKPOLBPPARAATMNTSR1 | |
| SCHEMBL19820403 | 0.87 | KLK5 (0.53) | SYKPPARAATMCTSLCTSS | |
| SCHEMBL13046582 | 0.87 | KLK5 (0.53) | SYKPPARAATMCTSLCTSS | |
| SCHEMBL22791589 | 0.86 | CTSS (0.57) | SYKPOLBPPARAATMCTSL | |
| SCHEMBL31027104 | 0.85 | SYK (0.57) | SYKPOLBPPARAATMNTSR1 | |
| SCHEMBL10604129 | 0.85 | SYK (0.57) | SYKPOLBPPARAATMNTSR1 | |
| SCHEMBL25054282 | 0.84 | CTSK (0.58) | SYKPPARAATMCTSLCTSS | |
| SCHEMBL20043006 | 0.84 | POLB (0.45) | SYKPOLBATMCTSLL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | SLC2A1, SLC2A4, SLC2A9 | SYK 1629/4885POLB 3155/4885PPARA 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.